BTIG lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $75 but keeps a Buy rating on the shares after its Q4 results and guidance. The quarter was not a major surprise to the bar set for 2025, but the pivotal data readout for the company’s CRC blood test in mid-2025 is a major catalyst for the stock, even though there could be some competitive dynamics that may weigh on the stock in the near term, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Positive Growth Outlook for Exact Sciences Driven by Cologuard Momentum and New Product Launches
- Promising Growth and Strategic Innovation Drive Buy Rating on Exact Sciences
- Exact Sciences price target lowered to $65 from $72 at BofA
- Exact Sciences: Poised for Long-Term Growth with Strategic Product Launches and Revenue Gains
- Exact Sciences price target lowered to $65 from $70 at Barclays